Sulforaphane preconditioning sensitizes human colon cancer cells towards the bioreductive anticancer prodrug PR-104A

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Erzinger, Melanie M ^a   Bovet, Cédric ^a   Hecht, Katrin M ^a   Senger, Sabine ^a   Winiker, Pascale ^a   Sobotzki, Nadine ^a   Cristea, Simona ^a,b   Beerenwinkel, Niko ^a,b   Shay, Jerry W ^c   Marra, Giancarlo ^d   Wollscheid, Bernd ^a   Sturla, Shana J ^a  

^a ETH ZURICH   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETOREDUCTASE 1C3; ANTINEOPLASTIC AGENT; PR 104A; SULFORAPHANE; TUMOR PROTEIN; UNCLASSIFIED DRUG; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; CHLORMETHINE DERIVATIVE; ISOTHIOCYANIC ACID DERIVATIVE; PR-104A; PRODRUG; SULFORAFAN;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DNA CROSS LINKING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; EPITHELIUM CELL; HT 29 CELL LINE; HUMAN; HUMAN CELL; UPREGULATION; COLON TUMOR; CYTOLOGY; DIPLOIDY; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

3-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIPLOIDY; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTESTINAL MUCOSA; ISOTHIOCYANATES; NITROGEN MUSTARD COMPOUNDS; PRODRUGS;

EID: 84961784305     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150219     Document Type: Article

References (58)

1. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nature Rev Cancer. 2011; 11:393-410.
2. Erzinger MM, Sturla SJ. Bioreduction-Mediated Food-Drug Interactions: Opportunities for Oncology Nutrition. Chimia. 2011; 65:411-5. PMID: 21797170
3. Mandlekar S, Hong J-L, Kong A-NT. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr Drug Metab. 2006; 7:661-75. PMID: 16918318
4. Veeranki OL, Bhattacharya A, Marshall JR, Zhang Y. Organ-specific exposure and response to sulfo-raphane, a key chemopreventive ingredient in broccoli: implications for cancer prevention. Br J Nutr. 2013; 109:25-32. doi: 10.1017/S0007114512000657 PMID: 22464629
5. Juge N, Mithen R, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007; 64(9):1105-27. PMID: 17396224
6. James D, Devaraj S, Bellur P, Lakkanna S, Vicini J, Boddupalli S. Novel concepts of broccoli sulforaph-anes and disease: induction of phase II antioxidant and detoxification enzymes by enhanced-glucora-phanin broccoli. Nutr Rev. 2012; 70:654-65. doi: 10.1111/j.1753-4887.2012.00532.x PMID: 23110644
7. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013; 27:2179-91. doi: 10.1101/gad.225680.113 PMID: 24142871
8. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regu-lated Genes Induced by the Chemopreventive Agent Sulforaphane by Oligonucleotide Microarray. Cancer Res. 2002; 62(18):5196-203. PMID: 12234984
9. Hu R, Hebbar V, KimB-R, Chen C, Winnik B, Buckley B, et al. In Vivo Pharmacokinetics and Regulation of Gene Expression Profiles by Isothiocyanate Sulforaphane in the Rat. J Pharmacol ExpTher. 2004; 310:263-71. PMID: 14988420
10. Konwinski RR, Haddad R, Chun JA, Klenow S, Larson SC, Haab BB, et al. Oltipraz, 3H-1, 2-dithiole-3-thione, and sulforaphane induce overlapping and protective antioxidant responses in murine microglial cells. Toxicol Sci. 2004; 116:422-32.
11. Bhamre S, Sahoo D, Tibshirani R, Dill DL, Brooks JD. Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate CancerCells. Prostate. 2009; 69:181-90. doi: 10.1002/pros.20869 PMID: 18973173
12. Traka M, Gasper AV, Smith JA, Hawkey CJ, Bao Y, Mithen RF. Transcriptome Analysis of Human Colon Caco-2 Cells Exposed to Sulforaphane. J Nutr. 2005; 135:1865-72. PMID: 16046710
13. Gross-Steinmeyer K, Stapleton PL, Tracy JH, Bammler TK, Strom SC, Eaton DL. Sulforaphane-and Phenethyl Isothiocyanate-Induced Inhibition of Aflatoxin B1-Mediated Genotoxicity in Human Hepato-cytes: Role of GSTM1 Genotype and CYP3A4 Gene Expression. Toxicol Sci. 2010; 116:422-32. doi: 10.1093/toxsci/kfq135 PMID: 20442190
14. Agyeman AS, Chaerkady R, Shaw PG, Davidson NE, Visvanathan K, Pandey A, et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat. 2012; 132:175-87. doi: 10.1007/s10549-011-1536-9 PMID: 21597922
15. Angeloni C, Leoncini E, Malaguti M, Angelini S, Hrelia P, Hrelia S. Modulation of Phase II Enzymes by Sulforaphane: Implications for Its Cardioprotective Potential. J Agric FoodChem. 2009; 57:5615-22. doi: 10.1021/jf900549c PMID: 19456137
16. Mastrangelo L, Cassidy A, Mulholland F, Wang W, Bao Y. Serotonin Receptors, Novel Targets of Sulforaphane Identified by Proteomic Analysis in Caco-2 Cells. Cancer Res. 2008; 68:5487-91. doi: 10.1158/0008-5472.CAN-07-6171 PMID: 18593952
17. LeeC-H, JeongS-J, Yun S-M, Kim J-H, Lee H-J, Ahn KS, et al. Down-regulation of phosphoglucomu-tase3 mediates sulforaphane-induced cell death in LNCaP prostate cancer cells. ProteomeSci. 2010; 8:67-74. doi: 10.1186/1477-5956-8-67 PMID: 21159204
18. Angeloni C, Turroni S, Bianchi L, Fabbri D, Motori E, Malaguti M, et al. Novel Targets of Sulforaphane in Primary Cardiomyocytes Identified by Proteomic Analysis. PLoS One. 2013; 8:e83283. doi: 10.1371/journal.pone.0083283 PMID: 24349480
19. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007; 28:1485-90. PMID: 17347138
20. WangX-J, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008; 29(6):1235-43. doi: 10.1093/carcin/bgn095 PMID: 18413364
21. Minarini A, Milelli A, Fimognari C, Simoni E, Turrini E, Tumiatti V. Exploring the effects of isothiocya-nateson chemotherapeutic drugs. Expert Opin Drug Metab Toxicol. 2014; 10:25-38. doi: 10.1517/17425255.2013.843668 PMID: 24087843
22. Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer. 1999; 80:1223-30. PMID: 10376975
23. Begleiter A, Leith MK, Thliveris JA, Digby T. Dietary induction of NQO1 increases the antitumour activity of mitomycin Cin human colon tumours in vivo. Br J Cancer. 2004; 91:1624-31. PMID: 15467770
24. Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteo-mics. Mol Cell Proteomics. 2002; 1(5):376-86. PMID: 12118079
25. Geiger T, Wehner A, Schaab C, Cox J, Mann M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol Cell Proteomics. 2012; 11: M111 014050.
26. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, et al. Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104. Clin Cancer Res. 2007; 13:3922-32. PMID: 17606726
27. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, et al. DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity. Cancer Res. 2009; 69:3884-91. doi: 10.1158/0008-5472.CAN-08-4023 PMID: 19366798
28. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, et al. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol CancerTher. 2009; 8:1714-23. doi: 10.1158/1535-7163.MCT-08-1209 PMID: 19509245
29. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010; 70:1573-84. doi: 10.1158/0008-5472.CAN-09-3237 PMID: 20145130
30. Jamieson SMF, Gu Y, Manesh DM, El-Hoss J, Jing D, MacKenzie KL, et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol. 2014; 88:36-45. doi: 10.1016/j.bcp.2013.12.019 PMID: 24434189
31. Lin H-K, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM. Expression and chracterization of recombinant type 2 3-alpha-hydroxysteroid dehydrogenase (HSD) from human prostate. Demonstration of bifunctional 3alpha/17beta-HSD activity and cellular distribution. Mol Endocrinol. 1997; 11:1971-84. PMID: 9415401
32. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010; 65:791-801. doi: 10.1007/s00280-009-1188-1 PMID: 20012293
33. Abou-Alfa GK, Chan SL, Lin C-C, Chiorean EG, Holcombe RF, Mulcahy MF, et al. PR-104 plus sorafe-nib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011; 68:539-45. doi: 10.1007/s00280-011-1671-3 PMID: 21594722
34. McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, et al. A phase I trial of PR-104, apre-pro-drugof the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011; 11:432-44. doi: 10.1186/1471-2407-11-432 PMID: 21982454
35. McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phae Ib study of patients with advanced solid tumours. BMC Cancer. 2012; 12:496-506. doi: 10.1186/1471-2407-12-496 PMID: 23098625
36. Efstathiou JA, Liu D, Wheeler JMD, Kim HC, Beck NE, Ilyas M, et al. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA. 1999; 96:2316-21. PMID: 10051639
37. Di Pietro M, Bellver JS, Menigatti M, Bannwart F, Schnider A, Russel A, et al. Defective DNA Mismatch Repair Determines a Characteristic Transcriptional Profile in Proximal Colon Cancer. Gastroenterology. 2005; 129:1047-59. PMID: 16143142
38. Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, Souza RF, et al. Immortalized Epithelial Cells Derived From Human Colon Biopsies Express Stem Cell Markers and Differentiate In Vitro. Gastroenterology. 2010; 138:1012-21. doi: 10.1053/j.gastro.2009.11.052 PMID: 19962984
39. Abramoff MD, Magalhaes PJ, Ram SJ. Image Processing with Image J. Biophotonics International. 2004; 11(7):36-42.
40. Franken NAP, Rodermond HA, Stap J, Haverman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006; 1(5):2315-9. PMID: 17406473
41. Zhang Y, Wade KL, Prestera T, Talalay P. Quantitative Determination of Isothiocyanates, Dithiocarba-mates, Carbon Disulfide, and Related Thiocarbonyl Compounds by Cyclocondensation with 1, 2-Ben-zenedithiol. Anal Biochem. 1996; 239:160-7. PMID: 8811900
42. Pietsch KE, van Midwoud PM, Villalta PW, Sturla SJ. Quantification of Acylfulvene-and Illudin S-DNA Adducts in Cells with Variable Bioactivation Capacities. Chem Res Toxicol. 2013; 26:146-55. doi: 10.1021/tx300430r PMID: 23227857
43. Yu X, Erzinger MM, Pietsch KE, Cervoni-Curet FN, Whang J, Niederhuber J, et al. Upregulation of Human Prostaglandin Reductase 1 (PTGR1) Improves Efficacy of Hydroxymethylacylfulvene, an Antitumor Chemotherapeutic Agent. J Pharmacol ExpTher. 2012; 343:426-33. doi: 10.1124/jpet.112. 195768 PMID: 22895897
44. Pietsch KE, Neels JF, Yu X, Gong J, Sturla SJ. Chemical and Enzymatic Reductive Activation of Acylfulvene to Isomeric Cytotoxic Reactive Intermediates. Chem Res Toxicol. 2011; 24:2044-54. doi: 10.1021/tx200401u PMID: 21939268
45. Xia C, Bao Z, Tabassam F, Ma W, Qiu M, HuaS-b, et al. GCIP, a Novel Human Grap2andCyclin D Interacting Protein, Regulates E2F-mediated Transcriptional Activity. J Biol Chem. 2000; 275:20942-8. PMID: 10801854
46. Gasper AV, Traka M, Bacon JR, Smith JA, Taylor MA, Hawkey CJ, et al. Consuming Broccoli Does Not Induce Genes Associated with Xenobiotic Metabolism and Cell Cycle Control in Human Gastric Mucosa. J Nutr. 2007; 137:1718-24. PMID: 17585021
47. Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, Gerhäuser C. Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res. 2006; 599:76-87. PMID: 16500682
48. Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont M-A, Chevolleau S, et al. Sulforaphane, a Naturally Occurring Isothiocyanate, Induces Cell Cycle Arrest and Apoptosis in HT29 Human Colon Can-cerCells. Cancer Res. 2000; 60(1426-1433). PMID: 10728709
49. Fimognari C, Nüsse M, Berti F, Iori R, Cantelli-Forti G, Hrelia P. Isothiocyanates as novel cytotoxic and cytostatic agents: molecular pathway on human transformed and non-transformed cells. Biochem Pharmacol. 2004; 68:1133-8. PMID: 15313410
50. Gamet-Payrastre L, Lumeau S, Gasc N, Cassar G, Rollin P, Tulliez J. Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro. Anti-Cancer Drugs. 1998; 9:141-8. PMID: 9510500
51. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-7. doi: 10.1038/nature11003 PMID: 22460905
52. Yee DJ, Blalsanek V, Bauman DR, Penning TM, Sames D. Fluorogenic metabolic probes for direct activity readout of redox enzymes: Selective measurement of human AKR1C2 in living cells. Proc Natl Acad Sci USA. 2006; 103:13304-9. PMID: 16938874
53. Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer. 2010; 10:630-8. doi: 10.1038/nrc2901 PMID: 20703252
54. 3 Adductomic Approach. Anal Chem. 2015; 87:11706-13. doi: 10.1021/acs.analchem.5b02759 PMID: 26509677
55. Erzinger MM, Bovet C, Uzozie A, Sturla SJ. Induction of Complementary Function Reductase Enzymes in Colon Cancer Cells by Dithiole-3-thione versus Sodium Selenite. J Biochem Mol Toxic. 2015; 29:10-20.
56. Shao Y, Pardini L, Pardini RS. Dietary Menhaden Oil Enhances Mitomycin C Antitumor Activity Toward Human Mammary Carcinoma MX-1. Lipids. 1995; 30:1035-45. PMID: 8569432
57. Scott O, Galicia-Connolly E, Adams D, Surette S, Vohra S, Yager JY. The Safety of Cruciferous Plants in Humans: A Systematic Review. J Biomed Biotechnol. 2012; 2012:503241. doi: 10.1155/2012/503241 PMID: 22500092
58. Gu Y, Atwell GJ, Wilson WR. Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans. Drug Metab Dispos. 2009; 38:498-508. doi: 10.1124/dmd.109.030973 PMID: 20019245